Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835226 | 0.92 | KDM5A (0.36) | KDM5AKDM5BPTGER4RORCCYP3A4 | |
| SCHEMBL6831808 | 0.91 | HTR7 (0.36) | KDM5AKDM5BKDM4EPARK7PTGER1 | |
| SCHEMBL6831758 | 0.91 | TSHR (0.39) | KDM4EPARK7 | |
| SCHEMBL6835396 | 0.89 | MRGPRX4 (0.37) | PRKAG1PRKAA2PRKAB1KDM4EPARK7 | |
| SCHEMBL6835323 | 0.86 | RXRA (0.39) | PRKAG1PRKAA2PRKAB1KDM5BPARK7 | |
| SCHEMBL6831716 | 0.86 | MAPT (0.42) | RORC | |
| SCHEMBL6831719 | 0.84 | NR4A2 (0.39) | KDM5AKDM5BPTGER4CYP2C9KDM4E | |
| SCHEMBL6835320 | 0.83 | PARK7 (0.46) | KDM4EPARK7 | |
| SCHEMBL6837172 | 0.83 | ALDH1A1 (0.45) | — | |
| SCHEMBL6834726 | 0.79 | EPHX2 (0.43) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | HICKS JAMES LESTER (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP26, MMP9 | PRKAG1 3975/4885PRKAA2 3662/4885PRKAB1 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.